Appeal No. 1995-3148
Application No. 08/011,130
6. A pharmaceutical composition comprising a pharmaceutical vehicle and a
molecular conjugate having a polymer backbone coupled with a plurality of binding
molecules which lack an Fc portion and which are specific for an antigen on a T cell.
8. A pharmaceutical composition of claim 6, wherein the polymer is hydrophilic,
stable, nonimmunogenic in humans, and resistant to hydrolysis in human body fluids.
11. A mixture of two or more molecular conjugates combined with a
pharmaceutical vehicle, each comprising a polymer backbone coupled with a plurality of
binding molecules of one class, each class being specific for different monovalent
antigenic epitopes on the same antigen on T cells, and all said binding molecules lacking
an Fc portion.
13. A pharmaceutical composition comprising a pharmaceutical vehicle and a
molecular conjugate having a polymer backbone coupled with a plurality of different
binding molecules which each bind noncompetitively to monovalent antigenic epitopes on
the same antigen on T cells, and all said binding molecules lacking an Fc portion.
The references relied on by the examiner are:
Goers et al. (Goers) 4,867,973 Sep. 19, 1989
J.M. Williams, et al. (Williams), “The Events of Primary T Cell Activation Can Be Staged by
Use of Sepharose-Bound Anti-T3 (64.1) Monoclonal Antibody and Purified Interleukin 1,”
Journal of Immunology, Vol. 135, No. 4, (1985), pp. 2249-2255.
T. Geppert, et al. (Geppert), “Accessory Cell Independent Proliferation of Human T4 Cells
Stimulated by Immobilized Monoclonal Antibodies to CD3,” Journal of Immunology, Vol.
138, No. 6, (1987), pp. 1660-1666.
Roitt, Immunology, Gower Medical Publishing (1995), page 8.7, figure 8.19.
Claims 6 and 8 through 14 stand rejected under 35 U.S.C. § 103. As evidence of
obviousness, the examiner relies on Williams, Geppert, Goers and Roitt. Claims 6
2
Page: Previous 1 2 3 4 5 6 7 8 Next
Last modified: November 3, 2007